Theralase(R) Investor Conference Call Reminder

Theralase(R) Reminds Investors of Conference Call to Provide Update on Study II Interim Data Demonstrating 64.3% Complete Response

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. **(TSXV: TLT) (OTCQB: TLTFF)** ("**Theralase®**" or the "**Company**"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on **Wednesday, November 19th at 11:00 am ET** to provide an update on the Company's ongoing Phase II clinical study for patients diagnosed with Bacillus Calmette-Guérin ("**BCG**")-Unresponsive Non-Muscle Invasive Bladder Cancer ("**NMIBC**") Carcinoma In-Situ ("**CIS**") ("**Study II**"), along with a review of financial and operational results for the fiscal quarter ended September 30, 2025.

Participants are encouraged to submit questions in advance to **mperraton@theralase.com** to ensure sufficient time for discussion.

Zoom Meeting Link: **https://us02web.zoom.us/j/81044841120**
Webinar ID: 810 4484 1120

Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom

An archived version will be available on the website following the conference call.

Study II Update:

As of **November 7, 2025**:

- **88 patients** have been treated with the primary Study Procedure, representing **97.8%** of the targeted enrollment of 90 patients
- **72 patients** have completed the clinical study, having been assessed at all required visits or removed by the principal investigator for lack of response
- **16 patients** remain pending study completion

Interim Clinical Results Demonstrate:

- **64.3% (54/84)** of patients achieved a **Complete Response ("CR")** at any point in time.
- **72.6% (61/84)** achieved a **Total Response (TR = CR + Indeterminate Response ("IR"))**.
- At the **450-day assessment**,
  - **40% (18/45)** of patients maintained a CR
  - **42.2% (19/45)** maintained a TR, demonstrating durability of response.

Theralase® remains on track to **complete enrollment in 4Q2025**, with **data lock and regulatory submissions expected in 1Q2027**.

Financial Update:

Theralase® has released its unaudited, condensed, consolidated, interim **3Q2025 financial statements** for the period ended September 30, 2025.

Financial Highlights - Nine Months Ended September 30, 2025 versus 2024:

- Revenue decreased **5%** to **$590,573** from $622,984.
- Cost of sales decreased **10%** to **$299,743** (51% of revenue).
- Gross margin remained stable at **$290,830** (49% of revenue).
- Selling expenses decreased **18%** to **$212,421**.
- Administrative expenses increased **12%** to **$1,444,687**.
- Research and development expenses increased **1%** to **$2,116,540**, reflecting increased activity to support Study II progress.
- Net loss increased **3%** to **$3,435,145**, including **$708,521** in non-cash expenses such as amortization and stock-based compensation.

Operational Highlights:

- **$672,627** raised via non-brokered private placement (July 28, 2025)
- **Warrant extensions** completed August 29, 2025
- **$280,000** in outstanding short-term loans as of November 7, 2025 at 15% interest
- The Company continues to evaluate **equity and non-dilutive funding opportunities** to support clinical and commercial milestones

For additional information, please refer to the Company's **Management's Discussion and Analysis** ("**MD&A**") available at www.sedarplus.ca.

About Ruvidar®:

Ruvidar® (TLD-1433) is a small molecule, able to be activated by light, radiation, sound and other drugs, intended for the safe and effective destruction of cancer, bacteria and viruses.

About Theralase® Technologies Inc.:

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of cancer, bacteria and viruses, with minimal impact on surrounding healthy tissue.

Additional information is available at www.theralase.com and www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

*This news release contains Forward-Looking Statements ("**FLS**") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "**may**", "**should**", "**will**", "**anticipates**", "**believes**", "**plans**", "**expects**", "**estimate**", "**potential for**" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.*

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical

studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.

For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.

For More Information:

1.866.THE.LASE (843.5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com

To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/274715